- Home
- SFWL vs CLSD Comparison
SFWL vs CLSD Comparison
Compare SFWL & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- CLSD
- Stock Information
- Founded
- SFWL 2001
- CLSD 2011
- Country
- SFWL China
- CLSD United States
- Employees
- SFWL N/A
- CLSD N/A
- Industry
- SFWL Trucking Freight/Courier Services
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- CLSD Health Care
- Exchange
- SFWL Nasdaq
- CLSD Nasdaq
- Market Cap
- SFWL 82.3M
- CLSD 68.4M
- IPO Year
- SFWL 2023
- CLSD 2016
- Fundamental
- Price
- SFWL $1.16
- CLSD $3.54
- Analyst Decision
- SFWL
- CLSD Hold
- Analyst Count
- SFWL 0
- CLSD 4
- Target Price
- SFWL N/A
- CLSD $4.33
- AVG Volume (30 Days)
- SFWL 24.2K
- CLSD 652.7K
- Earning Date
- SFWL 08-27-2025
- CLSD 11-11-2025
- Dividend Yield
- SFWL N/A
- CLSD N/A
- EPS Growth
- SFWL 31.68
- CLSD N/A
- EPS
- SFWL 0.14
- CLSD N/A
- Revenue
- SFWL $540,461,000.00
- CLSD $4,166,000.00
- Revenue This Year
- SFWL N/A
- CLSD $98.20
- Revenue Next Year
- SFWL N/A
- CLSD $213.77
- P/E Ratio
- SFWL $8.11
- CLSD N/A
- Revenue Growth
- SFWL 21.10
- CLSD N/A
- 52 Week Low
- SFWL $0.86
- CLSD $0.29
- 52 Week High
- SFWL $1.60
- CLSD $4.43
- Technical
- Relative Strength Index (RSI)
- SFWL 52.98
- CLSD 23.39
- Support Level
- SFWL N/A
- CLSD $4.68
- Resistance Level
- SFWL $1.27
- CLSD $5.33
- Average True Range (ATR)
- SFWL 0.09
- CLSD 0.47
- MACD
- SFWL -0.04
- CLSD -0.06
- Stochastic Oscillator
- SFWL 89.53
- CLSD 1.65
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.